PubMed Health⌕ Search

Biomedical subjects

R B Bolin

Publications and source records attributed to R B Bolin.

23 records · Page 2Linked to original sources
PubMedDate not supplied

In vitro evaluation of platelets stored in CDP-adenine formulations.

Little information is available about the effect of adenine and added glucose on stored platelets. Two new formulations, CPDA-2 and CPDA-3, contain 34 mg adenine per 63 ml preservative and extra glucose (1.75 and 2.0 times the glucose in standard CPD). We have studied the in vitro integrity of platelet concentrates stored in CPD, CPDA-1, CPDA-2, and CPDA-3 at 22 C for 72 hours. Morphology score, pH, platelet size, population distribution parameters, and electron microscopic ultrastructure did not show any adverse effects which could be ascribed to the presence of adenine or extra glucose or both. No differences in platelet adenosine triphosphate (ATP) concentration or plasma glucose utilization during storage were found between CPD and CPDA-1 platelets. The results suggest that adenine and added glucose in these preservatives are not detrimental to platelets in vitro by the measures employed.

Adenine↗
PubMedDate not supplied

Effect of delayed refrigeration on plasma factors in whole blood collected in CPDA-2.

Extension of the time within which whole blood may be separated into components offers logistic advantages for the operation of remote mobile drawing teams. We evaluated the effect of an 8-hour hold of whole blood at room temperature before preparation of components. Plasma coagulation activity and opsonic factor content were studied in 14 units drawn into the anticoagulant-preservative solution citrate-phosphate-dextrose-adenine (CPDA-2). At the time of collection, an additional 7-ml aliquot was drawn into 1 ml of CPDA-2, the plasma separated and frozen immediately. Components were prepared from whole blood units allowed to rest undisturbed at 22 +/- 1 degrees C for 8 hours. After 8 hours, a significant decrement of about 10 percent was found in the concentration of fibrinogen, plasminogen, fibronectin, and activity of Factor V. Factor VIII activities (VIIIAHF and VIIIAGN) were not significantly different after 8 hours. Our results indicate that room temperature storage for 8 hours before component processing has minimal effects on potentially labile plasma protein factors using CPDA-2 anticoagulant-preservative solution.

Adenine↗
PubMedDate not supplied

An in vivo comparison of CPD and CPDA-2 preserved platelet concentrates after an 8-hour preprocess hold of whole blood.

To see if citrate-phosphate-dextrose-adenine-two (CPDA-2) anticoagulant-preservative had an effect on the viability of platelets, we studied autologous in vivo recovery and survival in humans for platelet concentrates prepared from six units of blood drawn into CPDA-2 and compared them to six units drawn into citrate-phosphate-dextrose (CPD). These units were prepared from whole blood held at room temperature for 8 hours after collection and were then stored for 3 days at 22 +/- 2 degrees C. The recovery for platelets preserved in CPD was 39.0 +/0 4.8 percent and for platelets preserved in CPDA-2, 32.5 +/- 4.4 percent. The difference was not significant (p greater than 0.10). In order to estimate population differences, in vitro effects on in vivo viability were also evaluated. Six in vitro variables were studied but only pH at 72 hours (r = 0.77), platelet count (r = 0.64), and morphology score (r = 0.66) correlated to recovery. Only pH at 72 hours significantly influenced recovery (p = 0.007). By adjusting for individual pH differences, mean recovery for platelets stored in CPD was 37.5 percent, and for platelets stored in CPDA-2, 34.0 percent. The mean lifespan was 6.7 +/- 0.7 days for platelets preserved in CPD and 6.1 +/- 1.0 days for those preserved in CPDA-2. Although hemostatic function was not studied, these data support in vitro observations that platelets preserved with CPDA-2 are not different from platelets preserved with CPD, even after 8-hours of storage of whole blood at room temperature prior to platelet concentrate preparation.

Blood Platelets↗
PubMedDate not supplied

Glycerol-glucose cryopreservation of platelets. In vivo and in vitro observations.

Extended storage of platelets can be achieved by cryopreservation. However, most cryopreservation techniques require extensive manipulation prior to administration, limiting their practicality. A simple cryopreservative system using glycerol and glucose as cryoprotectants would eliminate the need to wash the platelets after freezing, since neither of these agents is toxic. We evaluated such a system in vivo and compared the results to 72-hour liquid-stored platelets. The percentage of in vivo recovery was significantly less (p less than 0.01) for cryopreserved (21.1 +/- 3.4% [chi +/- 1 SD]) than liquid-stored (43.8 +/- 7.4%) platelets, but those frozen-thawed cells that were viable had normal survivals (8.4 +/- 1.7 days). Liquid-stored cell appeared to be less viable (5.9 +/- 1.8 days). These results indicate that cryopreservation with the glycerol-glucose system produces significant injury to the majority of platelets and therefore, is inadequate for general blood bank use.

Blood Platelets↗